Terlipressin Administration for Hepatorenal Syndrome

Introduction to Terlipressin Therapy

• The American Association for the Study of Liver Diseases recommends terlipressin as a continuous IV infusion starting at 2 mg/day for hepatorenal syndrome, providing similar efficacy to bolus dosing but with significantly fewer adverse events 1, 2

Dosing and Administration

• The initial dose of terlipressin should be 2 mg/day as a continuous IV infusion, with dose escalation every 24-48 hours up to a maximum of 12 mg/day if serum creatinine does not decrease 1, 2, 3
• The European Association for the Study of the Liver suggests an initial dose of 0.5-1 mg every 4-6 hours, increasing to a maximum of 2 mg every 4-6 hours if serum creatinine reduction is less than 25% after 2-3 days 1, 2

Concomitant Albumin Administration

• The administration of 1 g/kg IV albumin on day 1, followed by 20-40 g/day IV for the duration of terlipressin therapy, is recommended by the American Association for the Study of Liver Diseases 1, 2, 3, 4

Treatment Duration and Response Assessment

• Treatment should be continued until complete response, defined as serum creatinine ≤1.5 mg/dL for at least 48 hours, or for a maximum duration of 14 days 1, 2, 3
• The response definitions include complete response, with serum creatinine <1.5 mg/dL, and partial response, with a ≥50% decrease in serum creatinine but still >1.5 mg/dL 1, 2

Administration Requirements and Monitoring

• The American Association for the Study of Liver Diseases recommends peripheral IV line administration and monitoring of vital signs every 2-4 hours, including pulse oximetry 1, 2, 4

Predictors of Response and Outcome

• Favorable predictors of response include baseline bilirubin <10 mg/dL, baseline serum creatinine <5 mg/dL, and lower ACLF grade 4
• Early response to terlipressin predicts improved survival, with each 1 mg/dL reduction in creatinine reducing mortality risk by 27% 6